Recipharm’s Erdosteine molecule will be tested in a clinical study as an add-on treatment for COVID-19 patients. The clinical study, which began on April 7th, is being conducted in clinical centers involved in COVID-19 treatment in Milan and Bergamo. Both Milan and Bergamo are based in Lombardy, the Italian region most affected by the virus. The study involves around 100 patients affected by COVID-19 and discharged from hospitals. It is evaluating if Erdosteine improves respiratory symptom...